Traders should monitor the AACR presentations for any unexpected efficacy or safety signals that could influence sentiment around HUTCHMED's pipeline, particularly HMPL-A580's potential as a first-in-class agent. No immediate catalyst for valuation change is indicated.
Price Chart
Executive Summary
HUTCHMED announced upcoming presentations of preclinical data for its novel ATTC candidate HMPL-A580 and updated clinical trial results for surufatinib combinations at the AACR 2026 conference. The data highlight the company's pipeline progress in precision oncology, with no new financial or regulatory developments disclosed.
Key Facts
- Preclinical data for HMPL-A580, a first-in-class PI3K/PIKK-EGFR Antibody-Targeted Therapy Conjugate, will be presented at AACR 2026.
- HMPL-A580 demonstrated robust anti-tumor effects in preclinical models, with favorable pharmacokinetic properties and a strong bystander effect.
- Updated results from a Phase Ib/II trial of surufatinib plus sintilimab and capecitabine in metastatic small bowel adenocarcinoma and appendiceal carcinoma will be shared.
- Results from an exploratory Phase II study of surufatinib combined with gemcitabine and nab-paclitaxel in pancreatic cancer will also be presented.
- All presentations are scheduled for poster sessions at AACR Annual Meeting 2026 in April.
Financial Impact
No financial impact disclosed; this is a scientific update ahead of data presentation.
Risk Factors
- Clinical data may not meet expectations when formally presented.
- HMPL-A580 remains in preclinical development, with uncertain path to clinical success.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001648257-26-000024 |
| Document: hcm-20260409x6k.htm | 0001648257-26-000024 |
| Document: 0001648257-26-000024-index-headers.html | 0001648257-26-000024 |
| Document: 0001648257-26-000024-index.html | 0001648257-26-000024 |
| Document: 0001648257-26-000024.txt | 0001648257-26-000024 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
May 21, 2026 22w ago | 6-K | $2.16 $2.16 | · 0.00% | ▼ −4.30% | $2.16 (+0.00%) |
May 12, 2026 23w ago | 6-K | $2.82 $2.16 | ▼ −23.40% | ▼ −27.79% | $2.16 (−23.40%) |
Apr 29, 2026 25w ago | 6-K | $2.82 $2.16 | ▼ −23.40% | ▼ −27.52% | $2.16 (−23.40%) |
Apr 9, 2026 28w ago | 6-K | $2.82 $2.90 | ▲ +2.84% | ▼ −7.94% | $2.16 (−23.40%) |
Apr 9, 2026 28w ago | 6-K | $2.82 $2.90 | ▲ +2.84% | ▼ −7.94% | $2.16 (−23.40%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers